Coverage
-
December 04, 2025
Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood pressure medication, according to a Wednesday filing.
18 other articles on this case.
View all »